Shuttle Pharmaceuticals Holdings, INC DEF 14A proxy statements

Shuttle Pharmaceuticals Holdings, Inc. seeks shareholder approval for a reverse stock split of up to 1-for-150 to maintain Nasdaq listing compliance.

Shuttle Pharmaceuticals is seeking stockholder approval for two proposals to issue more than 20% of its common stock at a discount to market price, aiming to secure funding for its Phase 2 clinical trial of Ropidoxuridine.

Shuttle Pharmaceuticals is asking stockholders to approve a reverse stock split, an increase in shares reserved for its equity incentive plan, and the issuance of common stock upon conversion of convertible notes.

Shuttle Pharmaceuticals reports progress on its lead program, Ropidoxuridine, and seeks shareholder approval for a reverse stock split to maintain Nasdaq compliance.

Shuttle Pharmaceuticals is asking shareholders to approve a reverse stock split while advancing its lead drug candidate, Ropidoxuridine, into a Phase 2 clinical trial for glioblastoma.